Rhenman & Partners Asset Management AB boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 31.3% during the 4th quarter, HoldingsChannel reports. The fund owned 165,818 shares of the specialty pharmaceutical company’s stock after purchasing an additional 39,496 shares during the quarter. Jazz Pharmaceuticals makes up 2.3% of Rhenman & Partners Asset Management AB’s portfolio, making the stock its 11th biggest holding. Rhenman & Partners Asset Management AB’s holdings in Jazz Pharmaceuticals were worth $20,555,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in Jazz Pharmaceuticals by 12.1% in the second quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock valued at $1,143,203,000 after acquiring an additional 715,595 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Jazz Pharmaceuticals by 0.5% in the third quarter. Vanguard Group Inc. now owns 4,882,984 shares of the specialty pharmaceutical company’s stock valued at $820,975,000 after acquiring an additional 23,400 shares in the last quarter. Vanguard Group Inc boosted its holdings in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc now owns 4,882,984 shares of the specialty pharmaceutical company’s stock valued at $820,975,000 after buying an additional 23,400 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 2.7% during the 3rd quarter. BlackRock Inc. now owns 4,490,714 shares of the specialty pharmaceutical company’s stock valued at $755,024,000 after buying an additional 118,634 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Jazz Pharmaceuticals by 3.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,912,173 shares of the specialty pharmaceutical company’s stock valued at $321,494,000 after buying an additional 56,291 shares in the last quarter. Institutional investors and hedge funds own 94.70% of the company’s stock.

JAZZ opened at $125.08 on Monday. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $7.55 billion, a PE ratio of 13.08, a P/E/G ratio of 0.76 and a beta of 1.17. Jazz Pharmaceuticals PLC has a 1 year low of $113.52 and a 1 year high of $184.00.

JAZZ has been the topic of a number of research reports. Cowen set a $200.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 7th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, November 7th. Royal Bank of Canada set a $184.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 7th. Piper Jaffray Companies set a $208.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 7th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $201.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $190.35.

In other news, EVP Suzanne Sawochka Hooper sold 3,334 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, December 14th. The stock was sold at an average price of $140.21, for a total value of $467,460.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Matthew P. Young sold 700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $150.00, for a total value of $105,000.00. Following the completion of the transaction, the chief financial officer now directly owns 32,068 shares of the company’s stock, valued at approximately $4,810,200. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,234 shares of company stock valued at $602,314. 3.90% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2019/02/11/jazz-pharmaceuticals-plc-jazz-position-increased-by-rhenman-partners-asset-management-ab.html.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: Price-Sales Ratio

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.